What is Bright Uro?
Founded in 2021 and headquartered in Aliso Viejo, California, Bright Uro operates at the intersection of advanced engineering and clinical urology. The company focuses on developing innovative medical devices designed to improve patient outcomes in pelvic health and urodynamic diagnostics. By addressing critical gaps in current diagnostic and therapeutic workflows, Bright Uro has established itself as a high-growth entity within the medical technology landscape. Its market position is bolstered by a commitment to precision engineering and a deep understanding of the complex requirements inherent in gastrointestinal and pelvic health care delivery systems.
How much funding has Bright Uro raised?
Bright Uro has raised a total of $74.7M across 4 funding rounds:
Angel/Seed
$6M
Series A
$23M
Stock/Share Issuance
$31M
Stock/Share Issuance
$14.7M
Angel/Seed (2022): $6M with participation from Academy Investor Network
Series A (2023): $23M led by Laborie
Stock/Share Issuance (2025): $31M, investors not publicly disclosed
Stock/Share Issuance (2025): $14.7M, investors not publicly disclosed
Key Investors in Bright Uro
Laborie
A global leader in pelvic and gastrointestinal health, Laborie specializes in the manufacturing of diagnostic equipment and consumables for clinical urodynamic testing.
Academy Investor Network
A venture capital group that focuses on supporting early-stage companies with high-growth potential, often leveraging a network of experienced professionals.
Undisclosed Investor
An undisclosed institutional participant providing strategic capital to support the company's ongoing research and development objectives.
What's next for Bright Uro?
With the recent infusion of capital, Bright Uro is poised to transition into a more aggressive scaling phase. The strategic roadmap likely involves expanding its clinical trial footprint and enhancing its manufacturing capabilities to meet the growing demand for sophisticated urodynamic testing solutions. As the company moves beyond its initial development stages, the focus will shift toward commercialization and market penetration, leveraging its existing partnerships to integrate its proprietary technology into broader clinical environments. This trajectory suggests a long-term commitment to setting new standards in urological care, potentially positioning the firm for further institutional backing or strategic acquisition as it matures.
See full Bright Uro company page
